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Abstract: Diagnosis and classification of aggressive mature B-cell lymphoma with atypical morphology remains a 
challenge. To identify factors that may contribute to the atypical morphology, we selected eight such cases and 
evaluated their morphologic, immunophenotypic and cytogenetic features and clinical outcomes. The neoplastic 
cells showed a diffuse monotonous infiltrating pattern with a spectrum of morphology including: 1) L1 
lymphoblastic; 2) centroblastic; 3) immunoblastic; and 4) mixed centroblastic and immunoblastic. The lymphoma 
cells in most cases were positive for CD10 and/or BCL6, and showed BCL2 expression. 6 of 8 cases showed C-
MYC rearrangements, and interestingly, all 6 cases demonstrated a proliferation index of <90%. 3 of the 6 cases 
also demonstrated t(14;18). Clinical follow-up indicated that aggressive mature B-cell lymphoma may benefit from 
more intensified chemotherapeutic regimens used for BL. Our study suggests that aggressive mature B-cell 
lymphoma with atypical morphology may be another “grey zone lymphoma” lying in the spectrum between Burkitt 
lymphoma and diffuse large B-cell lymphoma. 
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Classical Burkitt lymphoma (BL) is 
characterized morphologically by a diffuse 
proliferation of monotonous medium-sized 
lymphoma cells with round nuclei, small 
nucleoli and high proliferative as well as 
apoptotic indices. Interspersed in the sea of 
round "blue" cell tumor are Tingible-body 
macrophages with abundant clear cytoplasm 
and apoptotic bodies, imparting a "starry-sky" 
pattern of the neoplasm at low magnification 
[1]. BL is invariably associated with C-MYC 
over-expression as a result of C-MYC gene 
rearrangements. In contrast, diffuse large B-
cell lymphoma (DLBCL) includes a 
heterogeneous group of intermediate to high-
grade mature B cell neoplasms. The 
lymphoma cells are usually larger and show 
more variation in cell size and the amount of 
cytoplasm with vesicular chromatin and more 
prominent nucleoli [2]. 
 
Because of the drastic difference in molecular 
mechanism, treatment regimens and clinical 
outcomes, it is imperative to correctly 
diagnose and classify BL or DBLCL. With the 
help of immunophenotyping and cytogenetics, 
it is usually possible to differentiate classical 
BL from typical DLBCL. Both lymphomas are 
positive for all the mature B-cell markers, and 
sometimes CD10 and BCL6. Classical BL has a 
nearly 100% proliferation index and is always 
negative for BCL2 [3]. On the other hand, 
DLBCL in general shows a <90% proliferation 
index and is frequently positive for BCL2 [4]. In 
addition, C-MYC gene rearrangements are 
present in virtually all classical BLs, but only in 
a minority of DLBCLs. 
 
Problem arises when morphology of the 
lymphoma cells is not characteristic of either 
BL or DLBCL, herein referred to as aggressive 
mature B-cell lymphoma with atypical 
morphology. On one hand, the lymphoma cells 
are monotonous resembling classical BL or 
lymphoblastic lymphoma; however, they 
usually have more abundant cytoplasm, 
irregular nuclei, and sometimes more 
prominent nucleoli, consistent with the 
 
Zhao et al/C-MYC Rearrangements in Aggressive Mature B-Cell Lymphoma 
cytological features of DLBCL. On the other 
hand, these cells do not show the variations in 
size and shape usually seen in typical DLBCL. 
Recognizing this problem, a provisional entity 
of “atypical Burkitt/Burkitt-like lymphoma” was 
introduced to define some of these cases with: 
1) a characteristic BL immunophenotype; 2) a 
nearly 100% proliferation index; and 3) 
consistent presence of C-MYC translocations 
in the most recent WHO lymphoma 
classification [2]. Cases that do not fulfill all 
three criteria are currently considered to be 
DLBCL. However, more recent molecular 
evidence indicates that these criteria do not 
completely differentiate BL from DLBCL, and a 
reproducible distinction between BL and 
DLBCL is not always possible [5]. 
 
In this small series, we present 8 cases of 
aggressive mature B-cell lymphoma with 
atypical morphology. Although these cases 
may fall into the category of DLBCL by the 
current WHO classification, due to their 
atypical features and high clinical suspicion for 
BL, these cases were extensively analyzed by 
immunohistochemistry and fluorescence in 
situ hybridization (FISH). The results indicate 
that these cases may represent another “grey 
zone lymphoma” lying in the spectrum 
between BL and DLBCL.  
 
Materials and Methods 
 
Selection of Cases 
 
All cases in this study were selected from the 
archives of the Department of Pathology, 
Barnes-Jewish Hospital and the Laboratories 
of Pathology, University of Maryland Medical 
Center from July 2004 to June 2006. This 
selection was based on the clinical suspicion 
of BL, atypical morphology and available 
cytogenetic data. None of the patients had a 
documented history of HIV infection. The 
Institutional Review Boards from both 




Cervical lymph node or bone marrow biopsies 
were performed on most patients, with one 
half of the specimens fixed in 10% 
formaldehyde and the other half submitted for 
immunophenotypic analysis. Tissue sections 
were prepared from the formalin-fixed and 
paraffin-embedded biopsies using standard 
techniques. The sections were stained with 
routine hematoxylin-eosin (H&E). The 
morphology was reviewed independently by 
two hematopathologists. When there was 
discrepancy, FISH studies using the C-MYC 
break-apart and IGH/BCL2 dual fusion probe 
sets were performed. A consensus diagnosis 
was reached based on morphology, 
immunophenotype and the status of C-MYC 





Immunohistochemical stains were performed 
using a Biotek Techmate 1000 autostainer 
(Ventana Medical Systems, Tucson, AZ) 
according to the manufacturer's protocol. 
Mouse anti-human CD3, CD5, CD20, CD79a, 
BCL2, BCL6, Ki-67, MUM-1 and TdT (DAKO 
Corporation, Carpenteria, CA) were used as the 
primary antibodies. Horseradish peroxidase-
labeled rabbit anti-mouse polyclonal 
antibodies were employed to convert the 
chromogen 3, 3’-diaminobenzidine tetrahydro-
chloride substrate. All stains were performed 
with appropriate positive and negative 
controls. The proliferation indices were 
expressed as percentages and calculated 
using the formula (number of Ki-67+ 
cells/number of CD20+ cells) x 100. The 
number of CD79a+ cells was used in the 
formula for the CD20-negative case (patient 
3). Background T-cells were excluded from 
assessment of the proliferation indices. 
 
Flow Cytometric Immunophenotyping 
 
Immunophenotyping was performed using the 
FC500 four-color flow cytometer (Beckman-
Coulter, Miami, FL) according to the standard 
protocol (Becton-Dickinson, San Jose, CA). 
Directly conjugated monoclonal antibodies 
(Beckman-Coulter, Miami, FL) to the following 
antigens were used for this analysis: CD3 
(UCHT-1), CD4 (SFC112T4D11), CD5 
(SFC124T6G12), CD7 (8H8.1), CD8 
(SFC121Thy2D3), CD10 (J5), CD19 (PC5), 
CD20 (B9E9), CD23 (HD50), CD45 (J.33), 
CD79a (HM47), FMC7 (FMC7), HLA-DR (Immu-
357) and terminal deoxynucleotidyl 
transferase (TdT) (HT1+HT4+HT8+HT9). 
Directly conjugated monoclonal antibodies 
against CD2 (55.2) were obtained from 
Becton-Dickinson, San Jose, CA. Polyclonal 
rabbit anti-human immunoglobulin light chains 
were obtained from DakoCytomation, 
Carpenteria, CA. All antibodies were 
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conjugated with fluorescein isothiocyanate 
(FITC), phycoerythrin (PE), peridinin chlorophyll 
protein (PCP) or allophycocyanin (APC). The 
flow cytometric data was analyzed using 
CellQuest software (Becton-Dickinson, San 
Jose, CA). 
 
Fluorescence In Situ Hybridization (FISH) 
Analysis 
 
Dual-color FISH was performed either on 
lymph nodes or on cells from bone marrow as 
previously described [6]. Commercially 
available dual color break-apart C-MYC and 
dual fusion IGH/BCL2 probe sets were used 
following the manufacturer’s instructions 
(www.Vysis.com). The LSI MYC Dual Color, 
Break Apart Rearrangement Probe is a mixture 
of two probes that hybridize to opposite sides 
of the C-MYC gene (The SpectrumOrangeTM 
labeled 5' LSI MYC probe begins upstream of 
the 5' end of C-MYC and extends 260 kb 
toward the centromere. The SpectrumGreenTM 
3' LSI MYC probe starts about 1 Mb 3' of C-
MYC and extends toward the telomere for 
about 400 kb) (www.Vysis.com). This probe set 
can detect the C-MYC rearrangements involved 
in almost all the breakpoints for 
t(8;14)(q24;q32), t(8;22)(q24;q11) and 
t(2;8)(p11;q24). For FISH on lymph nodes, thin 
sections (5-6 μm) from formalin-fixed paraffin-
embedded block were mounted on poly-L-
lysine–coated slides. After deparaffinization, 
the sections were subjected to “antigen 
retrieval” using “steam cooking” in citrate 
buffer for 20 minutes, followed by re-hydration. 
After pepsin digestion at 37ºC for 30 minutes 
and a subsequent wash in 2 x SSC, the slides 
were allowed to air dry and followed by FISH 
analysis. After the hybridization, nuclei were 
counterstained with 4′6-diamidino-2-phenyl-
indole·2HCl (0.5 μL/mL), and the sections were 
viewed under an Olympus BX60 fluorescent 
microscope with appropriate filters (Olympus, 
Melville, NY). Hybridizations were digitally 
photo-graphed using a high-resolution COHU 
CCD black-and white camera, with a Z-stack 
motor programmed to capture images at 
sequential 4′6-diamidino-2-phenylindole·2HCl 
(1 level), fluorescein isothiocyanate (5 levels), 
and rhodamine (5 levels) filter settings. 
Reconstruction into a single superimposed 
image with blue, green, and red pseudocolors 
was accomplished using the CytoVision 





There were four in-house (patients 1, 3, 4 and 
7) cases and four outside consultation 
(patients 2, 5, 6 and 8) cases in this study. 
There was equal number of male and female 
patients. Their age ranged from 19 to 71 years 
with a median age of 63. The patient 
information, treatment regimens and clinical 
follow-up are summarized in Table 1. 
 
All lymphomas were composed of a 
monotonous population of neoplastic cells 
resembling BL. However, they demonstrated 
various atypical morphologic features often 
seen in DLBCL. These included L1 
lymphoblastic, centroblastic, immunoblastic, 
and mixed centroblastic and immunoblastic 
morphology (Figure 1). Unlike typical DLBCL, 
these cases showed less variation in size and 
shape of the neoplastic cells.  Some of the 
neoplastic cells have abundant basophilic 
cytoplasm, cytoplasmic vacuoles and 
prominent nucleoli (Figure 2). 
 
As summarized in Table 2, the lymphoma cells 
expressed CD20 in all but one cases. The 
lymphoma cells in the one CD20-negative case 
were positive for CD79a and expressed 
surface immunoglobulin light chain. BCL2 was 
positive in 5 of 6 cases that had C-MYC 
rearrangements. The lymphoma cells were 
either positive for both CD10 and BCL6 (3/8), 
or at least one of these two markers (4/8), 
indicating their germinal center origin. 
Interestingly, however, MUM-1 was positive in 
all 4 cases analyzed and in 2 of the 4 cases 
the lymphoma cells were positive for CD10. 
The lymphoma cells in 6 of 8 cases showed a 
<95% proliferation index. Extensive 
immunohisto-chemical studies were not 
performed on case 5 due to the lack of 
additional tissue. 
 
With the break-apart C-MYC probe, we 
identified the presence of C-MYC 
rearrangements in all 6 cases with <90% 
proliferation indices (Figure 3 and Table 2). 
Conversely, no C-MYC rearrangement was 
detected in the remaining 2 cases with >95% 
proliferation rates. Although C-MYC 
rearrangement is characteristic of BL, it has 
also been identified in rare cases of DLBCL [4, 
7]. In contrast, t(14;18) was present in about 
30% of DLBCL, but was never detected in 
classical BL [8]. To further characterize these
Int J Clin Exp Pathol (2008) 1, 65-74 67 





Table 1 Clinical information of the patients 
Case # Age/Sex Diagnosis Treatment Clinical outcome 
1 52/M Large B-cell lymphoma, stage IA; Status post failed 
autotransplant; Recurrence in CNS 
High dose methotrexate, ARA-C, Rituxan; 
intrathecal methotrexate and ARA-C 
Alive (8 years) with refractory 
disease; in hospice 
 
2 67/F High-grade large B-cell lymphoma Combined chemotherapy and radiation therapy Alive (22 months) with no 
evidence of disease 
 
3 71/M Low-grade B-cell lymphoma for 8 years; High-grade B-
cell lymphoma 
Salvage chemotherapy with CHOP Died of refractory disease (8 
months) 
 
4 64/F Large B-cell lymphoma CHOP+Rituxan, subsequently changed to CALGB 
trial with intrathecal therapy 
Alive (12 months) with no 
evidence of disease 
 
5 19/M Diffuse large B-cell lymphoma, stage IV Reduction with vincristine, prednisone and 
cyclophosphamide for 7 days; Induction with 
vincristine, prednisone, methotrexate, 
cyclophosphamide and doxorubicin for 7 days; 
Consolidation with methotrexate, hydrocortisone, 
ARA-C and prednisone 
 
Alive (24 months) with no 
evidence of disease 
6 71/M High-grade B-cell lymphoma CHOP+Rituxan x 4 cycles Alive (3 months) 
 
7 62/F Atypical Burkitt lymphoma High dose chemotherapy involving methotrexate 
with leukovorin rescue 
Died primarily of renal 
insufficiency 4 months after 
diagnosis 
 
8 36/F Diffuse large B-cell lymphoma CHOP+Rituxan x 6 cycles Alive (18 months) with no 
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CD20 CD79a CD10 BCL2 BCL6 MUM-1 KI-67 C-MYC IHG/BCL2 Others 
1 + NTa + + + + ~50% + + Polysomy 8 
2 + + - + + NT ~90% + NT None 
3 - +b + + - + ~70% + + None 
4 + - - + + + ~90% + - Polysomy 8 
5 + NT NT NT NT NT ~50% + - None 
6 + NT + + + NT ~90% + + None 
7 + + + + + NT ~100% - NT None 
8 + NT - - + + ~95% - - None 
aNT: Not tested; bby flow cytometry 
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Figure 1 Morphologic variations in aggressive mature B-cell lymphomas with atypical morphology (H&E, x 400 
magnification). A. L1 lymphoblastic morphology: a monotonous population of medium-sized neoplastic cells with 
scant cytoplasm, round nuclei and small nucleoli (from patient 3); B. Centroblastic morphology: large cells with 
abundant cytoplasm, vesicular nuclei and small nucleoli; C. Immunoblastic: large cells with abundant cytoplasm 
and single centrally located prominent nucleolus; D. Centroblastic and immunoblastic morphology: with features 
of (B) and (C). 
 
 
lymphomas, FISH studies were performed on 
all cases to evaluate the presence of 
IGH/BCL2 fusion gene associated with 
t(14;18). The results showed that IGH/BCL2 
was present in 3 of the 6 cases with C-MYC 
rearrangements and <90% proliferation 
indices (Table 2). However, t(14;18) was not 
detected in the remaining 2 cases with >95% 
proliferation indices and absent C-MYC 
rearrangements. As controls, FISH was also 
performed in two additional cases of classical 
BL and two additional cases of typical DLBCL. 
None of these cases harbored the 
t(14;18)(data not shown). 
 
The therapeutic regimens were modified 
accordingly based on the FISH results. Two 
cases (cases 1 and 4) with C-MYC 
rearrangements responded poorly to 
Rituximab (R), Cyclophosphamide (C), 
Adriamycin (H), Vincristine (O) and Prednisone 
(P) (R-CHOP) previously, but later responded 
favorably to intensified chemotherapy (Table 
1). After C-MYC rearrangement was identified, 
two cases (cases 2 and 5) were treated with 
either combined chemotherapy/radiation 
therapy or intensified chemotherapy; both are 
currently in remission for almost two or over 
two years. One patient (case 3) with C-MYC 
rearrangement failed salvage CHOP therapy 
and died, and another (case 6) was followed 
for only 3 months after R-CHOP. C-MYC 
rearrangements were not detected in two 
patients: one responded well to R-CHOP and 
remained disease-free for 18 months (case 8); 
the other was treated with high dose 
chemotherapy including methotrexate and 
died of renal failure 4 months after the 
diagnosis (case 7). Although the number of 
patients is small, it appears that patients with 
Zhao et al/C-MYC Rearrangements in Aggressive Mature B-Cell Lymphoma 
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Figure 2 Aggressive mature B-cell lymphoma with 
atypical morphology in bone marrow (from patient 
6). The bone marrow aspirate showed several large 
lymphoid cells with abundant basophilic and 
vacuolated cytoplasm, irregular nuclei and multiple 
prominent nucleoli (Wright-Giemsa, x 1000 
magnification). These cells have sizes similar to the 
adjacent promyelocyte and myelocytes. 
 
 
aggressive mature B-cell lymphoma with 
atypical morphology and C-MYC rearrange-
ments have benefited from the intensified 
chemotherapeutic regimens for BL rather than 




We retrospectively evaluated 8 cases of 
aggressive mature B-cell lymphoma with 
atypical morphology during a two-year period 
from two medical centers. C-MYC 
rearrangements are frequently found in these 
lymphomas (6/8, 75%). In addition, these 
lymphomas also frequently harbor t(14;18) 
(3/5, 60%) and/or trisomy 8 (2/6, 20%) 
genetic abnormalities. The current study 
indicates that these genetic abnormalities 
might be associated with the atypical 
morphology of aggressive B-cell lymphomas. 
Interestingly, C-MYC rearrangements are 
identified in all 6 cases with <
 
90% 
proliferation index, but are not detected in the 
remaining 2 cases with >95% proliferation 
index, demonstrating a poor correlation 
between the proliferation index and C-MYC 
rearrangements. Although this series is small, 
the results demonstrate the potential pitfall of 
using a near 100% proliferation rate as a 
surrogate marker for the diagnosis of BL. With 
overlapping features of BL and DLBCL, these 
aggressive mature B-cell lymphomas with 
atypical morphology may be another “grey 
 
Figure 3 FISH analysis using the c-MYC break-apart 
probe set. A. A c-MYC rearrangement is present 
(patient 1) as indicated by splitting apart of the 
normal red-green fusion signal into one red 
(centromeric end of MYC) and green (telomeric end 
of MYC) signal (arrows); B. An c-MYC rearrangement 
is absent (patient 8) as evidenced by the presence 
of normal red-green fusion signals only. 
 
 
zone lymphoma” lying between BL and DLBCL, 
and may require molecular studies to further 
define them [5, 9, 10]. 
 
How should these cases be classified based 
on the current information available? In 
addition to the neoplastic cells having a 
mature B-cell phenotype, they also express 
BCL2 as well as CD10 and/or BCL6, which are 
markers for germinal center B cells. Both BL 
and some of the DLBCL are believed to 
originate from the germinal center B-cells 
based on their expression of CD10 and/or 
BCL6 [11]. It is also believed that BCL2 
expression can only be detected in DLBCL, but 
not in BL [2-4]. However, Barth et al recently 
compared 7 endemic and 7 sporadic BL cases 
[12]. They found that a uniform expression of 
CD10 was seen only in endemic BL cases 
(7/7), and about half of the sporadic BL cases 
(4/7) were negative for CD10. One of the 
sporadic BL case also expressed BCL2 (1/7). A 
recent study of 220 aggressive mature B-cell 
Zhao et al/C-MYC Rearrangements in Aggressive Mature B-Cell Lymphoma 
lymphomas demonstrated that >20% of the 
molecular Burkitt lymphomas expressed BCL2 
[5]. In our study, most cases were positive for 
both BCL2 (6/7) and C-MYC rearrangements 
(6/8). Although the majority of our cases are 
BCL6-positive (6/7), almost half of our cases 
(3/7) are negative for CD10 (see Table 2). 
Considering the clinical behavior, the cases 
with C-MYC rearrangements (6/8) might have 
been atypical sporadic BL in retrospect. 
 
The t(8;14) and its variant chromosomal 
translocations are currently the most specific 
cytogenetic abnormalities for BL [3]. FISH 
analysis is one of the most sensitive 
approaches in identifying all these 
translocations in routine formalin-fixed 
paraffin-embedded tissue sections. However, 
the commonly used MYC/IGH probe can only 
detect the fusion in ~80% of the BL [13, 14]. 
Recently, the break-apart C-MYC probe set 
(Vysis) was developed to detect t(8;14) as well 
as the variant C-MYC rearrangements t(2;8) 
and t(8;22)[15]. We opted to use this probe 
set in this study because of its increased 
diagnostic sensitivity. Although the C-MYC 
partner genes are not identified by this 
approach, since IG-MYC is much more 
common in aggressive mature B-cell 
lymphomas [9], most of the partner genes in 
our cases are presumably IG. Since C-MYC 
gene may be activated by translocations with 
other partner genes [16], our approach may be 
able to detect those C-MYC rearrangements as 
well. With our approach, we have detected C-
MYC rearrange-ments in most (75%) of our 
cases of morphologically aggressive mature B-
cell lymphomas. The findings are clinically 
relevant because more and more studies 
suggested that DLBCL with C-MYC 
rearrangements might have a clinical course 
resembling BL [17, 18]. 
 
Half of our cases harbor the t(14;18) in 
addition to C-MYC rearrangements, which 
created a dilemma in classifying these 
lymphomas. Although lymphomas similar to 
our cases were lumped together with DLBCLs 
and the C-MYC rearrangement was considered 
a secondary event reflecting tumor 
progression [19], recent studies suggested 
that DLBCLs with both C-MYC rearrangements 
and t(14;18) behaved more aggressively 
clinically like BL [17, 18]. Therefore, even if 
the C-MYC rearrangement is indeed an event 
of progression, the emergence of t(8;14) in 
addition to the t(14;18) should perhaps justify 
the interpretation of progression to BL [20], 
and thus the lymphoma should be managed 
like BL. Further studies are needed to 
characterize mature B cell lymphomas with 
both C-MYC rearrangement and t(14;18) since 
their clinical management may be significantly 
different from either BL or DLBCL. 
 
To avoid under- or over-treatment of the 
patients, it is critical to distinguish BL from 
DLBCL when encountering these aggressive 
mature B-cell lymphomas with atypical 
morphology. Since diagnosis of BL requires 
strict criteria (CD10+, BCL6+, close to a 100% 
proliferation index and IG-MYC), many cases 
that do not meet all these criteria were 
diagnosed as DLBCL, and therefore would not 
receive the benefit of intensified 
chemotherapy. More recent studies [5, 9, 10] 
suggest that some of those DLBCL cases 
indeed had the molecular signatures of BL and 
over 10% of those molecular BL did not harbor 
any detectable C-MYC translocations [4]. 
 
In summary, we should recognize this group of 
aggressive mature B-cell lymphomas with 
atypical morphology and C-MYC rearrange-
ments when determining chemotherapy, since 
more and more studies show that they follow a 
similar clinical course as BL [17, 18]. Although 
molecular profiling may be the eventual 
solution [9, 10], it is not yet ready for real-time 
diagnosis [21]. Cytogenetic studies may be 
routinely performed in all aggressive mature B-
cell lymphomas with atypical morphology. With 
the increasing number of reported cases [5, 9, 
10, 17, 18], “aggressive mature B-cell 
lymphomas with atypical morphology” may 
emerge as another “grey zone lymphoma” 
between BL and DLBCL, and multicenter 
collaborative investigation is essential to 
further define the clinical, pathological and 
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